KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems, Inc. reported that Horton Capital Partners Fund, L.P. acquired 5,119 common shares as a grant/award on September 30, 2026, with a reported price of $0 per share. The fund’s reported indirect holdings after the award were 5,074,660 shares. The reporting persons were Joseph M. Manko Jr. (director and 10% owner), Horton Capital Management, LLC, Horton Capital Partners, LLC, and Horton Capital Partners Fund, L.P. (each identified as a 10% owner). Separately, 782,547 shares were listed as directly held as of September 30, 2026.
KORU Medical Systems, Inc. director Robert Cascella acquired 5,119 shares of Common Stock in a grant/award transaction on October 1, 2026, at a reported $2.93 per share. His direct Common Stock holdings following the transaction were 103,274 shares; the reported action was an award, not a purchase or sale.
KORU Medical Systems, Inc. director Matin Shahriar reported a grant or award acquisition of 5,119 common shares on October 1, 2026, at $2.93 per share. His direct holdings following the transaction were 106,263 shares.
KORU Medical Systems, Inc. director and Chairman of the Board R. John Fletcher received an award of 7,679 common shares on October 1, 2026. The transaction lists $2.93 per share. He directly held 239,836 shares after the award. This was a grant or award acquisition, rather than a reported market purchase.
KORU Medical Systems, Inc. director Edward Wholihan acquired 5,119 shares of common stock through a grant or award on October 1, 2026. The transaction lists a price of $2.93 per share. His directly held common stock position following the transaction was 56,431 shares.
KORU Medical Systems, Inc. director Donna French received a compensation-related grant/award of 5,119 common shares on October 1, 2026. The transaction was direct; her direct holdings following it were 103,633 shares. The reported per-share amount was $2.93; this was an award, not a market purchase.
KORU Medical Systems, Inc. (KRMD) reported that its Chief Commercial Officer, Adam R. Kalbermatten, purchased 32,000 shares of common stock on September 8, 2026, in an open-market or private transaction at $3.16 per share, bringing his directly held stake to 394,017 shares. The filing indicates this trade was not made pursuant to a Rule 10b5-1 trading plan, and it includes a standard disclaimer that the reporting person is not admitting beneficial ownership beyond what is required.
KORU Medical Systems, Inc. reports a governance change approved by its Board of Directors effective August 13, 2026. The company amended Section 3.05 of its Amended and Restated By-laws so that, consistent with the Delaware General Corporation Law, the authority to remove any director rests exclusively with shareholders through an affirmative vote of holders of a majority of the company’s outstanding shares.
The Board states it has never voted to remove a director and has no intention or agreement to do so. The amendment is filed as an exhibit to this report.
KORU Medical Systems, Inc. reported that Chief Commercial Officer Adam R. Kalbermatten had 75,000 shares of common stock delivered on July 28, 2026 upon vesting of previously granted restricted stock units, each converting into one share. On the same date, 25,483 shares were withheld at $4.26 per share to satisfy tax obligations related to the vesting. The transactions were reported as direct holdings and not under a Rule 10b5-1 trading plan.
KORU Medical Systems reported strong top-line growth for the quarter ended June 30, 2026. Net revenues rose to $12.0 million, up 18.2% year over year, led by domestic core growth of 12.4% and international core growth of 59.1%, partly offset by a 35.0% decline in pharma services and clinical trials revenue.
Gross profit increased to $7.8 million with gross margin improving to 65.1% from 63.5%, while operating expenses grew 6.3% to $7.2 million. The company generated quarterly net income of $252,449, compared with a net loss in the prior-year quarter. For the first six months, net revenues were $23.8 million, up 20.1%, and the net loss narrowed to $554,629.
Cash and cash equivalents were $8.3 million at June 30, 2026, with net cash provided by operating activities of $230,776. KORU also has an undrawn $5.0 million revolving credit facility and a $5.0 million term loan, both amended in March 2026 to extend maturities and reduce interest-rate floors, and expects available liquidity to fund requirements for at least the next twelve months.